Literature DB >> 25865963

Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.

Louise M Andrews1, Natalia Riva, Brenda C de Winter, Dennis A Hesselink, Saskia N de Wildt, Karlien Cransberg, Teun van Gelder.   

Abstract

INTRODUCTION: Starting doses of tacrolimus and ciclosporin are typically chosen on a calculated mg/kg bodyweight basis. After initiation of treatment, doses are adjusted with therapeutic drug monitoring (TDM). This trial-and-error approach has been accepted by most physicians and pharmacists involved in the care of transplanted patients. AREAS COVERED: Dosing algorithms have only fairly recently been proposed to better individualize the starting dose. This review provides an overview of all the currently available dosing algorithms in adult and children for the starting dose of ciclosporin, tacrolimus and mycophenolic acid. In these algorithms, multiple other covariates influencing the starting dose, such as age, hematocrit, comedication and genotype are taken into account. After selecting the starting dose with an algorithm and after initiation of treatment, TDM will, however, remain necessary. Whether or not implementation of such algorithms will improve clinical outcome remains to be demonstrated. EXPERT OPINION: First of all an algorithm needs to be validated, against an independent dataset. Second, in a prospective study the algorithm should prove to reduce the time to reach the target concentration, and to reduce the number of patients with drug concentrations (far) outside the therapeutic window. Finally, a clinical trial demonstrating a benefit on clinical outcome will be crucial in achieving broad acceptance of calculating starting dose using individualized dosing algorithms.

Entities:  

Keywords:  algorithm; ciclosporin; dose; equation; immunosuppressive drugs; kidney; liver; mycophenolic acid; pharmacokinetics; tacrolimus; therapeutic drug monitoring; transplantation

Mesh:

Substances:

Year:  2015        PMID: 25865963     DOI: 10.1517/17425255.2015.1033397

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  12 in total

1.  The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

2.  Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise.

Authors:  Guigao Lin; Xiao Zhang; Kuo Zhang; Yanxi Han; Liming Tan; Jinming Li
Journal:  J Clin Lab Anal       Date:  2018-04-30       Impact factor: 2.352

3.  A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.

Authors:  Franc Andreu; Helena Colom; Laure Elens; Teun van Gelder; Ronald H N van Schaik; Dennis A Hesselink; Oriol Bestard; Joan Torras; Josep M Cruzado; Josep M Grinyó; Nuria Lloberas
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients.

Authors:  M I Francke; W J Visser; D Severs; A M E de Mik-van Egmond; D A Hesselink; B C M De Winter
Journal:  Eur J Clin Pharmacol       Date:  2022-05-14       Impact factor: 3.064

Review 5.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

6.  Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose.

Authors:  Louise M Andrews; Brenda C M de Winter; Jiang-Tao Tang; Nauras Shuker; Rachida Bouamar; Ron H N van Schaik; Birgit C P Koch; Teun van Gelder; Dennis A Hesselink
Journal:  Transplant Direct       Date:  2017-01-19

7.  A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.

Authors:  Louise M Andrews; Dennis A Hesselink; Teun van Gelder; Birgit C P Koch; Elisabeth A M Cornelissen; Roger J M Brüggemann; Ron H N van Schaik; Saskia N de Wildt; Karlien Cransberg; Brenda C M de Winter
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

8.  A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients.

Authors:  Jiang-Tao Tang; Lin Yan; Lan-Lan Wang; Yang-Juan Bai; Ya-Mei Li; Yuan-Gao Zou; Yi Li; Teun van Gelder; Yun-Ying Shi
Journal:  Ann Transplant       Date:  2018-05-08       Impact factor: 1.530

9.  A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.

Authors:  L M Andrews; D A Hesselink; R H N van Schaik; T van Gelder; J W de Fijter; N Lloberas; L Elens; D J A R Moes; B C M de Winter
Journal:  Br J Clin Pharmacol       Date:  2019-01-17       Impact factor: 4.335

Review 10.  Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits.

Authors:  Yu-Kai Kuo; I-Chan Lin; Li-Nien Chien; Tzu-Yu Lin; Ying-Ting How; Ko-Hua Chen; Gregory J Dusting; Ching-Li Tseng
Journal:  J Clin Med       Date:  2019-08-15       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.